Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from 23andMe Holding ( (MEHCQ) ) is now available.
On June 30, 2025, 23andMe announced that it received court approval to sell substantially all of its assets to TTAM Research Institute, a nonprofit led by co-founder Anne Wojcicki, for $305 million. This transaction, part of 23andMe’s Chapter 11 bankruptcy proceedings, aims to continue the company’s mission under TTAM’s nonprofit model, ensuring privacy and data transparency for customers while advancing global health research.
The most recent analyst rating on (MEHCQ) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on 23andMe Holding stock, see the MEHCQ Stock Forecast page.
Spark’s Take on MEHCQ Stock
According to Spark, TipRanks’ AI Analyst, MEHCQ is a Neutral.
23andMe Holding’s overall stock performance is weak, primarily due to significant financial challenges, including declining revenues and persistent net losses. The technical analysis also suggests a bearish trend with no strong momentum to reverse it. The negative valuation metrics further highlight the company’s struggles with profitability. Improvements in financial performance and strategic adjustments to reverse negative trends are critical for enhancing investor confidence.
To see Spark’s full report on MEHCQ stock, click here.
More about 23andMe Holding
23andMe is a genetics-led consumer healthcare company focused on empowering individuals to access and understand their genetic information for health benefits. The company offers services such as Personal Genome Service and Research Services, and operates in the telehealth sector through Lemonaid Health.
Average Trading Volume: 538,945
Technical Sentiment Signal: Sell
Current Market Cap: $119.8M
See more insights into MEHCQ stock on TipRanks’ Stock Analysis page.